Medical Condition News

RSS

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.

20 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

Alcohol intake increases risk of many cancers

A large group of distinguished scientists published a very detailed and rather complex paper describing the association between alcohol consumption and cancer in the BMJ. It is based on data from the EPIC study in Europe, with a mean follow up of 8.8 years for more than 300,000 subjects.

20 Apr 2011

Tissue Genesis commences PVD clinical trials with adipose-derived adult stem cell-coated vascular grafts

Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.

20 Apr 2011

Dental diagnosis and treatment for snoring and sleep apnoea

Over seven million people in Spain are at risk of developing sleep apnoea (SA), a health problem caused by obstructed air intake during sleep.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

20 Apr 2011

Biomerix receives Health Canada licenses for REVIVE and ASSURE Hernia Repair Meshes

Biomerix Corporation announced today it has received two Class III Medical Device Licenses by Health Canada for its REVIVE and ASSURE Hernia Repair Meshes.

20 Apr 2011

Product name impacts dieters' food evaluations

Dieters are so involved with trying to eat virtuously that they are more likely than non-dieters to choose unhealthy foods that are labeled as healthy, according to a new study in the Journal of Consumer Research. It seems dieter focus on food names can work to their disadvantage.

20 Apr 2011

Medically vulnerable families can benefit from high-deductible health plans

People who are medically vulnerable -- those with low incomes or chronic health problems -- who enroll in high-deductible health plans are at no more risk for cutting back on needed health care than other people who enroll in the plans, according to a new RAND Corporation study.

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

Dogs develop cancer that is biologically similar to a human tumour

Despite steadily improving methods for its diagnosis and treatment, cancer still represents one of the most frequent causes of death in humans. What is less well known is that this also holds true for pets such as dogs.

20 Apr 2011

A cluttered brain doesn't remember

Lapses in memory occur more frequently with age, yet the reasons for this increasing forgetfulness have not always been clear. According to new research from Concordia University, older individuals have reduced learning and memory because their minds tend to be cluttered with irrelevant information when performing tasks.

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Alzheimer’s diagnostic guidelines released

Neurologists and experts have come up with a set of guidelines to better diagnose Alzheimer's disease in the clinic for the first time in nearly three decades. The advice also helps doctors identify the earliest signs of the degenerative condition, even before symptoms of memory loss begin. The hope is that they can help patients prepare early, and eventually treat, the disease.

19 Apr 2011

New guidelines allow definition of pre-Alzheimer's

The emphasis on the need to diagnose Alzeheimer's during its earliest stages is also evident in Congress, where legislation introduced this month would create new, specific Medicare cost codes for early-disease diagnosis to address these steps, including the discussions between the physician and caregivers.

19 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

Medical Condition News

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Alcohol intake increases risk of many cancers

Tissue Genesis commences PVD clinical trials with adipose-derived adult stem cell-coated vascular grafts

Dental diagnosis and treatment for snoring and sleep apnoea

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

Biomerix receives Health Canada licenses for REVIVE and ASSURE Hernia Repair Meshes

Product name impacts dieters' food evaluations

Medically vulnerable families can benefit from high-deductible health plans

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

Dogs develop cancer that is biologically similar to a human tumour

A cluttered brain doesn't remember

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Alzheimer’s diagnostic guidelines released

New guidelines allow definition of pre-Alzheimer's

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

Gene mutation in Tibetian Terrier dogs causes hereditary form of Parkinson's disease in humans

RaySearch receives order for its RayStation system from RISO

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News